Biotest AG

BIESFOTCHealthcare

$32.00

+$0.00(+0.00%)

Market Cap$1.6B

P/E Ratio—

52W High$32

52W Low$30.48

Avg Volume75

Open$32.00

Beta0.00

Overview

Biotest AG (BIESF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

BIESF · free cash flow · updated Jun 8, 2026

Core FCF metrics

BIESF · FCF · TTM · margin & CAGR

Free cash flow was $32.2M for FY2024 (fiscal year ending 2024-12-31), up 189.2% year-over-year The FCF margin was 4.4%.

FY2024 Free Cash Flow$32.2M▲ +189.2% YoY

Trailing 12M (TTM)−$14.3MTrailing 4Q sum · TTM negative vs latest FY positive

FCF Margin4.4%$32.2M ÷ revenue

3-Year CAGR+27.1%FY2021 → FY2024

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

BIESF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2024Latest$60.9M(29M)$32.2M▲ +189.2%4.4%

FY2023−$2.7M(33M)−$36.1M▲ +48.3%-5.3%

FY2022−$40.5M(29M)−$69.8M▼ 544.6%-13.5%

FY2021$33.9M(18M)$15.7M▲ +135.9%3.0%

FY2020−$16.7M(27M)−$43.7M▲ +35.5%-9.0%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

BIESF · P/FCF · FCF yield · FCF per share

Biotest AG (BIESF) valuation ratios are currently unavailable — market cap, share count, or TTM data could not be retrieved from our data provider.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

Valuation ratios are unavailable — market cap, share count, or TTM data could not be retrieved. Individual metrics are shown where available.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2024 · 2024-12-31

Cash flow statement summary

BIESF · cash flow statement · operating / investing / financing

For FY2024, Biotest AG generated $60.9M in operating cash flow and spent 29M in capital expenditures, yielding $32.2M in free cash flow.

Operating Activities

+$60.9M

Cash from core business operations

2024-12-31

Investing Activities

−$25.7M

CapEx, acquisitions & investments

2024-12-31

Financing Activities

−$35.4M

Buybacks, dividends & debt

2024-12-31

FCF FormulaOperating CF ($60.9M) − |CapEx| (29M) = FCF ($32.2M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

BIESF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Biotest AGYOU

BIESF

$32.2M+189.2%4.4%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Biotest AG (BIESF) reported free cash flow of $32.2M for FY2024 (fiscal year ending 2024-12-31), up 189.2% year-over-year. The FCF margin was 4.4%.

Based on available data, Biotest AG has maintained positive free cash flow for at least 5 fiscal year(s). FCF peaked at $48.5M in FY2010.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

BIESF free cash flow · 8 questions

Biotest AG free cash flow was $32.2M for FY2024, up 189.2% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$14.3M.

BIESF free cash flowBIESF FCFBIESF FCF 2024BIESF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Biotest AG · Biotest AG SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026